CTA 056 |
| Catalog No.GC50076 |
CTA 056은 IC50이 0.1μM인 ITK(IL-2 유도성 T 세포 키나제) 억제제입니다. CTA 056은 악성 T 세포를 선택적으로 표적화하고 온코미르를 조절합니다. CTA 056은 세포자멸사를 유도하고 T 세포 백혈병 및 림프종의 치료를 위한 잠재적인 치료제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1265822-30-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Interleukin-2-inducible T-cell kinase (ITK) inhibitor (IC50 values are 0.1, 0.4 and 5 μM for ITK, BTK and ETK, respectively). Inhibits growth of cancer cells expressing ITK, including MOLT-4 and Jurkat cells in vitro. Induces apoptosis in Jurkat cells. Inhibits MOLT-4 xenograft tumor growth in mice.
Guo et al (2012) Molecular characteristics of CTA056, a novel interleukin-2-inducible T-cell kinase inhibitor that selectively targets malignant T cells and modulates oncomirs. Mol.Pharmacol. 82 938 PMID:22899868
Average Rating: 5 (Based on Reviews and 15 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *